Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.
about
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantationModel for End-stage Liver DiseaseToward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinomaStrategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantationRegional variability in symptom-based MELD exceptions: a response to organ shortage?Concordance of hypervascular liver nodule characterization between the organ procurement and transplant network and liver imaging reporting and data system classifications.Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives.Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.Chemoembolization decreases drop-off risk of hepatocellular carcinoma patients on the liver transplant list.Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.Liver transplantation and cirrhotomimetic hepatocellular carcinoma: classification and outcomes.Impact of MELD allocation policy on survival outcomes after liver transplantation: a single-center study in northeast Brazil.Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma.Epidemiology of hepatitis B in the United States.Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United StatesHepatocellular carcinoma: therapy and prevention.Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes.Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.Expanded criteria for liver transplantation in patients with hepatocellular carcinoma.Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card.Development of a survival evaluation model for liver transplant recipients with hepatocellular carcinoma secondary to hepatitis B.Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus.Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis.Long-term experience with liver transplantation for hepatocellular carcinoma.Evidence-based development of liver allocation: a review.What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?Is tumor biopsy necessary?Liver Transplantation for HCC: A Review.Treatment of hepatocellular carcinoma: a systematic review.Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach.Operative outcomes of adult living donor liver transplantation and deceased donor liver transplantation: a systematic review and meta-analysis.Efficacy of the American Association for the Study of Liver Disease and Barcelona criteria for the diagnosis of hepatocellular carcinoma.Liver transplantation for hepatocellular carcinoma: past, present and future.Recent advances in the surgical treatment of hepatocellular carcinoma.Financial Impact of Liver Sharing and Organ Procurement Organizations' Experience With Share 35: Implications for National Broader Sharing.Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation.Seeding of the rectus sheath with hepatocellular carcinoma after image guided percutaneous liver biopsy using coaxial biopsy needle system.Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.Long-term trends in chronic hepatitis B virus infection associated liver transplantation outcomes in the United States.MELD-good for many, not as good for others … at least for now.
P2860
Q26852105-BB3308D2-7AB7-4995-89FC-69BE9FBBCC46Q26864971-AAF262D4-DF63-449C-9C5D-11B83B780E73Q26999411-A98AA952-41D5-4A78-B6D7-5CEE78D3C4B9Q27005375-06DC846B-76D0-48B2-8226-2C608C65186CQ30454559-1AAA3AB2-790D-4924-B35C-095DF0364936Q30867625-33BC57EA-0A11-4186-BBD9-0123C968A1EEQ33237223-234B7ADB-1587-436B-B037-9C7820E40C88Q34021608-D48867FD-773F-4DCD-9881-BE92B1CABCDCQ34065055-57128E1B-814C-4A24-AE40-B0899B1F77CCQ34080984-73224C13-B3E4-484C-A224-E8FDDDB88F27Q34096867-121C799D-2C22-4A3A-B176-98DD833F9ECBQ34603872-E39B5167-D95A-48A0-8086-A580FCF990ABQ35621307-1E82C763-1F39-4F51-A37E-A2615D33DD0BQ35792051-D0702B9C-ABA5-40EA-B58D-D6DDD02F7818Q35991480-3352D82D-9E50-41CA-A029-F3B204DCEA0CQ36377949-9F35B052-999E-4CE5-92C9-F0CF2330CE41Q36497118-2B066BEE-EFA6-4EBC-9B1C-F1C161DA2DB3Q36716640-71157752-CF71-4A6C-8133-9C4237453D01Q36945075-D10B5ECA-19DA-4EE1-98AD-BDD4B6DCADB7Q37045547-E03353C3-B418-4602-A974-94DB47FF5373Q37212974-194ECAA2-917F-4227-A29F-556DD1C819E7Q37356370-6824BD27-F621-4B56-84F4-535B861B4A18Q37636484-E78913DE-D357-4C7F-8622-947D64ADA0A3Q37780114-E1FBE4FC-1DFD-4757-928C-77FDE1F9DD27Q37880205-7D36979A-6505-4BF8-AA80-AEB9CE538328Q37886890-322B1616-AB25-4DAA-8A64-530F73407364Q37899841-FD056C6A-5458-400F-A640-BA8E1787E91CQ38078347-B22AFDFA-73D8-45E9-81FB-8B7FDE1F725DQ38155508-B9A03022-F8F5-47C5-9C82-00BA55414965Q38168622-CE7F2F78-EEFF-4D80-93D9-77DFA8F197D2Q38183336-CD856D6B-8F56-4A5D-AB2E-07E24671BA42Q38202030-2EC833E8-FC09-487E-9399-36FC26AE91D8Q38211859-F32FFDCF-9D23-4976-AA94-314CD1D871CDQ38262115-CBF9E9C4-B723-4369-99E5-8858B09843B2Q38386767-10BEF031-3FF5-4848-ACDF-80B466FDB0DDQ39277521-F7D223BE-8041-4463-BFCE-324B5FAC754CQ39459371-FA53C2D5-C57F-4BB9-A2C7-2737A085C922Q39652155-42BEBAEF-169A-453A-833E-F2CD9E57F02AQ40302269-A7363293-A16B-42C7-B710-FF3DE8A72860Q40707369-3A634E40-FC4A-4123-B252-83F1611F7A82
P2860
Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Liver transplantation for hepa ...... of the MELD allocation policy.
@ast
Liver transplantation for hepa ...... of the MELD allocation policy.
@en
type
label
Liver transplantation for hepa ...... of the MELD allocation policy.
@ast
Liver transplantation for hepa ...... of the MELD allocation policy.
@en
prefLabel
Liver transplantation for hepa ...... of the MELD allocation policy.
@ast
Liver transplantation for hepa ...... of the MELD allocation policy.
@en
P2093
P1433
P1476
Liver transplantation for hepa ...... of the MELD allocation policy.
@en
P2093
David C Mulligan
Richard B Freeman
Russell H Wiesner
P304
P356
10.1053/J.GASTRO.2004.09.040
P407
P433
P577
2004-11-01T00:00:00Z